로딩 중…
지수 로딩 중…
Chong Kun Dang Pharmaceutical Corp.
185750· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩67,500+1.81%
2026-08-04
Financials
Valuation Metrics
Chong Kun Dang Pharmaceutical Corp.'s Market Cap is ₩9317B. At end of 2025 it was ₩1.1T. Ranked #303 of 2,436 in KR market (top 12%), #227 of 787 on KOSPI (top 29%), #35 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 15%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 931.69B KRW | KR#303/2,436 Sec#35/234 |
| Revenue | 1.74T KRW | KR#274/2,436 Sec#7/234 |
| Net Income | 78.57B KRW | KR#267/2,436 Sec#18/234 |
| Total Assets | 1.83T KRW | KR#310/2,436 Sec#13/234 |
| Net Assets | 1.03T KRW | KR#279/2,436 Sec#15/234 |
| Employees | 2,336 | KR#124/2,436 Sec#5/234 |
| Value | ||
| P/E | 11.86x | KR#827/2,436 Sec#49/234 |
| P/B | 0.91x | KR#1,418/2,436 Sec#91/234 |
| PEG | 1.90x | KR#795/2,436 Sec#52/234 |
| P/S | 0.54x | KR#996/2,436 Sec#45/234 |
| EV/EBITDA | 13.57x | KR#803/2,436 Sec#47/234 |
| FCF Yield | -7.90% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 7.64% | KR#731/2,436 Sec#48/234 |
| ROA | 4.29% | KR#740/2,436 Sec#62/234 |
| Op. Margin | 4.73% | KR#960/2,436 Sec#76/234 |
| Revenue Growth | 11.67% | KR#860/2,436 Sec#75/234 |
| Earnings Growth | 6.24% | KR#859/2,436 Sec#57/234 |
| Financial Health | ||
| Debt Ratio | 178.06% | KR#1,517/2,436 Sec#173/234 |
| Total Debt | 358.42B KRW | KR#357/2,436 Sec#16/234 |
| FCF | -73.56B KRW | KR#2,116/2,436 Sec#209/234 |
| Cash | 174.56B KRW | KR#303/2,436 Sec#13/234 |
| Current Ratio | 2.00x | KR#948/2,436 Sec#109/234 |
| Net Debt/EBITDA | 2.24x | KR#911/2,436 Sec#66/234 |
| Dividend | ||
| Div. Yield | 0.75% | KR#1,217/2,436 Sec#76/234 |
| Div. Growth | -54.55% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -18.08% | KR#1,172/2,436 Sec#94/234 |
| 1M Return | -2.17% | KR#1,002/2,436 Sec#87/234 |
| From 52W High | -36.80% | KR#599/2,436 Sec#38/234 |
| 1Y MDD | -34.39% | KR#329/2,436 Sec#21/234 |
| Trading | ||
| Volume | 27,500 shares | KR#1,726/2,436 Sec#164/234 |
| Foreign Own. | 16.05% | KR#290/2,436 Sec#16/234 |
| Per Share | ||
| EPS | 5,691 KRW | KR#154/2,436 Sec#10/234 |
| BPS | 77,891 KRW | KR#169/2,436 Sec#9/234 |
Company Info
동사는 1941년 궁본약방으로 설립되어 2013년 인적분할을 통해 의약품사업부문을 담당하는 신설회사로 재편되었으며, 유가증권시장에 재상장함. 국내 대형 제약사로서 신약 캄토벨과 듀비에정, 네스플 출시하였고 2023년 노바티스사와 HDAC6 저해제 CKD-510 기술수출 계약 체결함. 동사는 신약, 바이오의약품 연구개발과 해외시장 개척을 통해 글로벌 제약기업으로 도약하고 있음. 종근당는 2013년에 설립되었으며 서울 서대문구에 본사를 두고 있습니다.